Posted by Michael Wonder on 27 Jun 2019
Agenda for the August 2019 PBAC intracycle meeting
27 June 2019 - The agenda for the PBAC meeting to be held on 23 August 2019 is now available.
At this stage, the PBAC will consider only one industry submission - a major submission from Celgene for lenalidomide (Revlimid) for use in combination with bortezomib and dexamethasone by patents with newly diagnosed multiple myeloma who are ineligible for a primary stem cell transplant.
